These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

In July 2023, Leqembi (lecanemab; Eisai and Biogen), a DMT mAb that binds to amyloid protofibrils, was granted traditional approval by the US Food and Drug Administration (FDA), based on phase 3 ...

This accumulation could elevate their risk of developing late-onset amyloid-related disorders, such as Alzheimer’s disease.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

The accumulation of beta-amyloid protein in the brain is considered an early pathological brain change in Alzheimer's disease, although the exact cause of amyloid accumulation is unknown.